$SWIM

Kunchala Suraj sold (to issuer) $63K of SWIM

Kunchala Suraj (VICE PRESIDENT & CONTROLLER) sold (to issuer) 8,693 shares of Latham Group, Inc. (SWIM) at $7.29 on 2026-08-07.

Original reporting
SEC EDGAR · Kunchala Suraj
Published Aug 11, 2026, 12:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SWIM
Neutral
low confidence
Mentioned
$SWIM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SWIMNeutralLow
01

Why it matters

The only new information is the insider sale details (shares, price, total value, and post-transaction holdings). There is no accompanying corporate event or performance update.

02

Market read

For traders, this is primarily a monitoring datapoint on insider behavior rather than a catalyst for repricing.

03

What to watch

The transaction is coded as a sale to the issuer, which can be administrative (for example, buyback participation or similar mechanics) and may not reflect bearish fundamentals.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-11 after-hours/market close window (per timestamp)

Background

The article is a SEC Form 4 insider transaction disclosure for Latham Group, Inc. (SWIM).

Company-level read

Ticker impact

$SWIMNeutralLow confidence
Context

Latham Group, Inc. (SWIM) disclosed an insider Form 4 sale to the issuer of 8,693 shares at $7.2900 on 2026-08-07.

Expected impact

Likely limited near-term impact; treat as low-signal unless follow-on filings show sustained selling or a change in insider behavior.

Evidence & confidence

The filing provides transaction details but does not include new guidance, earnings, contracts, or regulatory developments. Insider sales can be non-informational, and the article lacks context on motivation or broader insider activity.

Market effects

No clear sector read-through from a single insider sale to the issuer.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted as less routine, so traders may watch for additional insider selling or unusual volume around the filing date.

Key entities

  • Latham Group, Inc.

    Company subject of the Form 4 insider transaction disclosure (SWIM).

  • Kunchala Suraj

    Vice President and Controller who sold 8,693 shares to the issuer at $7.2900 on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Latham Group Refinances Capital Structure with New Credit Facilities

Latham Group (SWIM) refinanced its capital structure with new credit facilities totaling $375 million. The facilities include a $75 million revolving credit line and a $300 million term loan, both secured by company assets. Proceeds were used to repay existing debt. The facilities mature in 2031 and 2033, respectively, and include leverage-based interest margins and covenants.

$FULCMedAI 8/10

Latham Advises Frazier Life Sciences on Private Placement Financing in Connection With Fulcrum Therapeutics and Slate Medicines Merger

Fulcrum Therapeutics (Nasdaq: FULC) and Slate Medicines announced a definitive all-stock merger. The combined company will operate as Slate Medicines, Inc. and is expected to trade on Nasdaq as SLTE. Slate secured commitments for an oversubscribed concurrent private placement of $245 million led by Frazier Life Sciences, with other healthcare investors participating.

$SWIMMedAI 8/10

Latham Group (SWIM) Q2 2026 Earnings Call Transcript

Latham Group, Inc. (SWIM) reported Q2 2026 net sales of $197.5 million, up 14.4% year over year, driven by 10.3% organic growth and the Freedom Pools acquisition. Adjusted EBITDA rose to $44.6 million. Net income fell to $12.8 million due to a $5.0 million FX impact. Full-year guidance: net sales $600 million to $620 million, adjusted EBITDA $110 million to $120 million.

$LOGCMedAI 8/10

Latham Represents Blackstone Credit & Insurance in Financing for ContextLogic’s Acquisition of gChem for US$850 Million

ContextLogic Holdings (OTCQB: LOGC) said it will acquire gChem, the holding company of Gaylord Chemical and subsidiaries, from funds managed by EagleTree Capital and co-investors. The deal values gChem at an enterprise value of US$850 million. Financing will come from Blackstone Credit & Insurance, including a US$250 million term loan and US$25 million revolver, per the company.